WASHINGTON — The steady erosion of experienced staff at the Food and Drug Administration is slowly compromising the agency’s ...

Beyond staff cuts, the departures of some longtime investigators in recent months have left less experienced people tasked ...

Around 3,500 FDA employees received termination emails; FDA Commissioner Marty Makary suggests lowering industry user fees ...

Other agencies are moving forward with RIFs and terminations, but official tells federal court some plans have changed.

Cuts at the FDA are slowing inspections of overseas drug manufacturers, prompting concerns from former and current employees that medication safety could be at risk, ProPublica reported July 7. Dozens ...

In the first six months of 2025, 385 employees resigned from the Center for Drug Evaluation and Research, compared with under 130 staff during the same period last year.

The steady erosion of experienced staff is slowly compromising FDA work and low morale is pushing more workers to the exits ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

The Department of Health and Human Services finalized the layoffs of thousands of employees after a Supreme Court ruling cleared the way for the Trump administration to proceed with mass firings ...

Curay, the acting director of the FDA’s Center for Drug Evaluation and Research, internally announced her retirement Monday.